Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of Age

Trial Identifier: VAV00026
Sponsor: Sanofi
Start Date: July 2025
Primary Completion Date: February 2026
Study Completion Date: February 2026
Condition: Respiratory Syncytial Virus Immunisation; Healthy Volunteers

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

No locations posted.